£18.19
1.06% yesterday
London, Dec 02, 05:35 pm CET
ISIN
GB00BN7SWP63
Symbol
GSK

GlaxoSmithKline Stock price

£18.19
+0.77 4.45% 1M
+3.32 22.33% 6M
+5.29 41.03% YTD
+5.34 41.56% 1Y
+5.57 44.17% 3Y
+6.92 61.39% 5Y
+9.57 110.98% 10Y
+12.51 220.46% 20Y
London, Closing price Tue, Dec 02 2025
+0.19 1.06%
ISIN
GB00BN7SWP63
Symbol
GSK
Industry

New AI Insights on GlaxoSmithKline Insights AI Insights on GlaxoSmithKline

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
£72.3b
Enterprise Value
£86.8b
Net debt
£14.4b
Cash
£3.3b
Shares outstanding
4.0b
Valuation (TTM | estimate)
P/E
13.5 | 10.7
P/S
2.2 | 2.2
EV/Sales
2.7 | 2.6
EV/FCF
18.5
P/B
4.5
Dividends
DPS
£0.61
Yield 1Y | 5Y
3.4% | 5.3%
Growth 1Y | 5Y
9.4% | -5.5%
Payout 1Y | 3Y
98.4% | 33.6%
Increased
1 Year
Financials (TTM | estimate)
Revenue
£32.2b | £33.3b
EBITDA
£8.5b | £10.9b
EBIT
£8.4b | £9.2b
Net Income
£5.5b | £6.8b
Free Cash Flow
£4.7b
Growth (TTM | estimate)
Revenue
2.7% | 6.1%
EBITDA
6.8% | 33.6%
EBIT
6.5% | 12.9%
Net Income
118.8% | 163.8%
Free Cash Flow
-2.0%
Margin (TTM | estimate)
Gross
72.5%
EBITDA
26.5% | 32.9%
EBIT
26.2%
Net
17.1% | 20.4%
Free Cash Flow
14.6%
Financial Health
Equity Ratio
23.0%
Return on Equity
18.8%
ROCE
21.1%
ROIC
18.4%
Debt/Equity
1.1
More
EPS
£1.3
FCF per Share
£1.2
Short interest
-
Employees
69k
Rev per Employee
£460.0k
Show more

Is GlaxoSmithKline a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,078 stocks worldwide.

GlaxoSmithKline Stock Analysis

Unlock Scores for Free

Analyst Opinions

31 Analysts have issued a GlaxoSmithKline forecast:

14x Buy
45%
13x Hold
42%
4x Sell
13%

Analyst Opinions

31 Analysts have issued a GlaxoSmithKline forecast:

Buy
45%
Hold
42%
Sell
13%

Financial data from GlaxoSmithKline

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
32,166 32,166
3% 3%
100%
- Direct Costs 8,839 8,839
2% 2%
27%
23,327 23,327
3% 3%
73%
- Selling and Administrative Expenses 9,014 9,014
2% 2%
28%
- Research and Development Expense 6,272 6,272
5% 5%
19%
8,507 8,507
7% 7%
26%
- Depreciation and Amortization 80 80
48% 48%
0%
EBIT (Operating Income) EBIT 8,427 8,427
7% 7%
26%
Net Profit 5,494 5,494
119% 119%
17%

In millions GBP.

Don't miss a Thing! We will send you all news about GlaxoSmithKline directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The CET segment refers to the management of business activities. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Head office United Kingdom
CEO Emma Walmsley
Employees 68,629
Founded 1999
Website www.gsk.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today